IOVA research · 13F holders by reporting quarter
Iovance Biotherapeutics, Inc. (IOVA): 13F holders, 2026Q1
The largest share positions in IOVA that the managers Kresmion follows reported on Form 13F for 2026Q1, as filed. The current quarter, the company's SEC filings and its recent events are on the IOVA research page.
IOVA positions held by the managers we follow (2026Q1)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP FundCUSIP 462260100 · 2026Q1 | $48M | 0.04% | +211.2% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 462260100 · 2026Q1 | $33M | 0.02% | +3897.6% |
| D. E. Shaw & Co., Inc. FundCUSIP 462260100 · 2026Q1 | $28.1M | 0.02% | +109.3% |
| CITADEL ADVISORS LLC FundCUSIP 462260100 · 2026Q1 | $9.2M | 0.01% | n/a |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.